Solu-medrol and Progressive multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Progressive multiple sclerosis is reported as a side effect among people who take Solu-medrol (methylprednisolone sodium succinate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Ampyra, and have Gait disturbance.

The phase IV clinical study analyzes which people have Progressive multiple sclerosis when taking Solu-medrol. It is created by eHealthMe based on reports of 39,265 people who have side effects when taking Solu-medrol from the FDA, and is updated regularly.

What is Solu-medrol?

Solu-medrol has active ingredients of methylprednisolone sodium succinate. It is often used in multiple sclerosis. eHealthMe is studying from 39,410 Solu-medrol users. Check the latest studies of Solu-medrol.

What is Progressive multiple sclerosis?

Progressive multiple sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord) is found to be associated with 103 drugs and 114 conditions by eHealthMe. Check the latest studies of Progressive multiple sclerosis.

On Jul, 16, 2026

39,265 people reported to have side effects when taking Solu-medrol.
Among them, 24 people (0.06%) have Progressive multiple sclerosis.

Could Solu-medrol cause Progressive multiple sclerosis?

Among these 24 people:

How long have people been on Solu-medrol when they have Progressive multiple sclerosis? *

What is the gender of people who have Progressive multiple sclerosis when taking Solu-medrol? *

female: 52.17 %
male: 47.83 %

What is the age of people who have Progressive multiple sclerosis when taking Solu-medrol? *

What are other drugs people take besides Solu-medrol? *

What are other side effects people have besides Progressive multiple sclerosis? *

Fatigue (feeling of tiredness): 9 people, 37.50%
Fall: 9 people, 37.50%
Weakness: 8 people, 33.33%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 25.00%
Mobility Decreased (ability to move is reduced): 6 people, 25.00%
Gait Disturbance: 6 people, 25.00%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 20.83%
Stress And Anxiety: 5 people, 20.83%
Insomnia (sleeplessness): 4 people, 16.67%
Diabetes: 4 people, 16.67%

What are the existing conditions these people have? *

Gait Disturbance: 6 people, 25.00%
Fatigue (feeling of tiredness): 5 people, 20.83%
Urinary Tract Disorder: 3 people, 12.50%
High Blood Cholesterol: 3 people, 12.50%
Depression: 3 people, 12.50%
High Blood Pressure: 2 people, 8.33%
Sleep Disorder: 1 person, 4.17%
Premenstrual Dysphoric Disorder: 1 person, 4.17%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.17%
Adverse Reaction: 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Solu-medrol and have Progressive multiple sclerosis?

- Check whether Progressive multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Solu-medrol:

Solu-medrol (39,410 reports)

Progressive multiple sclerosis treatments and more:

Progressive multiple sclerosis (2,523 reports)

How severe was Progressive multiple sclerosis and when was it recovered:

Progressive multiple sclerosis in Solu-medrol

Expand to all the drugs that have ingredients of methylprednisolone sodium succinate:

Progressive multiple sclerosis and drugs with ingredients of methylprednisolone sodium succinate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Solu-medrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multiple sclerosis:

Progressive multiple sclerosis (103 drugs)

Browse all the conditions that are associated with Progressive multiple sclerosis:

Progressive multiple sclerosis (114 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone sodium succinate (the active ingredients of Solu-medrol) and Solu-medrol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.